17,261 trials
Primary Biliary Cholangitis
Primary: Fold Change in Serum Gamma-glutamyl Transferase (GGT) — 0.74; 0.41; 0.28; 0.31 fold-change — p=0.293
Neuroblastoma
Primary: Overall Responses — 3; 18; 12; 1 Participants
Jaundice, Neonatal · Hyperbilirubinemia, Neonatal
Primary: Total Serum Bilirubin (mg/dL) — 9.82; 9.97; 9.92; 8.48 mg/dL — p==0.0000021
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
Lipodystrophy
Primary: Total Body Insulin Sensitivity — 4.4; 10.9; 5.8; 6.4 mg/kg fat-free mass/min
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Primary: Progression Free Survival (PFS) — 19.1 Months
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 94.9; 92.0; 100.0; 93.8 percentage of participants
Traumatic Brain Injury
Primary: Percent Passing the Galveston Orientation Amnesia Test (GOAT) Within 28 Days Post Injury — 12; 14 Participants — p=0.99
Metastatic Melanoma
Primary: Clinical Responses Can be Obtained in Following Administration of RFT5-dgA
Influenza A H3N2
Primary: Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge). — 17956.5; 4502.6…
Anaplastic Large Cell Lymphoma, ALK-Negative · Recurrent Anaplastic Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 10 milligrams PO daily
Prostatic Neoplasms
Primary: Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone — 8; 13; 6; 10 months
Cancer
Primary: Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy — 10; 0; 0 Participants
Psoriasis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 67; 18 participants
Malaria
Primary: Safety and Tolerability of Administration of R21/Matrix-M1 Assessed by the Occurrence of Solicited Local and Systemic Adverse Events. — 10; 0 Number of adverse events